Investigating how the Nono pathway affects the immune response to oncolytic adenoviruses in cancer treatment
Official title: Examining the Role of Nono Pathway on the Innate Immunity Against Oncolytic Adenoviruses
Funded at University of Tx Md Anderson Can Ctr · NIH-11032361 · Data updated 2026-11-12
This study is looking at how a specific pathway in the immune system can help improve treatments using special viruses that target and kill cancer cells, especially for people with brain tumors, to make these therapies work better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | December 16, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $229,309 |
| NIH project number | 1R21CA283514-01A1 |
| Project ID | NIH-11032361 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with brain tumors who are undergoing or considering treatment with oncolytic adenoviruses.
✕Less likely to help
Patients with tumors that are not responsive to oncolytic adenoviruses or those who are not eligible for such treatments may not benefit from this research.
What this research studies
This research focuses on understanding the role of the Nono pathway in enhancing the innate immune response against oncolytic adenoviruses, which are viruses engineered to target and destroy cancer cells. By examining how this pathway influences the immune system's ability to fight tumors, the research aims to improve the effectiveness of viroimmunotherapy, particularly in patients with brain tumors. The approach involves studying the interactions between the virus and the immune system to identify ways to prolong the presence of the virus in tumors, thereby boosting the anti-tumor immune response. Patients may benefit from insights that could lead to more effective cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with brain tumors, potentially increasing survival rates and treatment efficacy.
How similar studies have gone: Previous studies have shown promising results with oncolytic virotherapy in brain tumors, indicating that enhancing immune responses could lead to significant advancements in treatment.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Gomez-Manzano, Candelaria — University of Tx Md Anderson Can Ctr
- Study coordinator: Gomez-Manzano, Candelaria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.